Prognostic factors for mortality, ICU, MIS-C and hospital admission due to SARS-CoV-2 in paediatric patients: A systematic review and meta-analysis

Constantine I. Vardavas^{1,2*}, Katerina Nikitara¹, Alexander G. Mathioudakis^{3,4}, Dimitris Delialis⁵, Valia Marou¹, Nithya Ramesh², Kimon Stamatelopoulos⁵, Georgios Georgiopoulos⁵, Revati Phalkey⁶, Jo Leonardi-Bee⁶, Charlotte Deogan⁷, Favelle Lamb⁷, Aikaterini Mougkou⁷, Anastasia Pharris⁷, Jonathan E. Suk⁷

1: School of Medicine, University of Crete, Heraklion, Crete, Greece

2: Department of Oral Health Policy and Epidemiology, Harvard School of Dental Medicine, Harvard University, Boston, MA, USA

3: Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK

4: North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

5: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

6: Centre for Evidence-Based Healthcare, Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, UK

7: European Centre for Disease Prevention and Control, Solna, Sweden

*Corresponding author:

Constantine Vardavas, School of Medicine, University of Crete, Heraklion, Crete, Greece,

e-mail: vardavasc@uoc.gr

ABSTRACT

Background: There is a paucity of data on the factors associated with severe COVID-19 disease, especially in children. This systematic review and meta-analysis aim to identify the risk factors for acute adverse outcomes of COVID-19 within paediatric populations, using the recruitment setting as a proxy of initial disease severity.

Methods: A systematic review and meta-analysis were performed representing published evidence from the start of the pandemic up to 14 February 2022. Our primary outcome was the identification of risk factors for adverse outcomes, stratified by recruitment setting (community, hospital). No geographical restrictions were imposed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to evaluate the certainty in the body of evidence for each meta-analysis. In anticipation of significant clinical and methodological heterogeneity in the meta-analyses, we fitted logistic regression models with random effects.

Findings: Our review identified 47 studies involving 94,210 paediatric cases of COVID-19. Infants up to 3 months were more likely to be hospitalised than older children. Gender and ethnicity were not associated with an increased likelihood of adverse outcomes among children within the community setting. Concerning comorbidities, having at least one pre-existing disease increased the odds of hospitalisation. Concerning BMI, underweight children and severely obese were noted to have an increased likelihood of hospital admission. The presence of metabolic disorders and children with underlying cardiovascular diseases, respiratory disorders, neuromuscular disorders and neurologic conditions were also more likely to be hospitalised. Concerning underlying comorbidities, paediatric hospitalised patients with congenital/genetic disease, those obese, with malignancy, cardiovascular diseases and respiratory disease were associated with higher odds of being admitted to ICU or ventilated.

Interpretation: Our findings suggest that age, male, gender, and paediatric comorbidities increased the likelihood of hospital and ICU admission. Obesity, malignancy, and respiratory and cardiovascular disorders were among the most important risk factors for hospital and ICU admission among children with COVID-19. The extent to which these factors were linked to actual severity or where the application of cautious preventive care is an area in which further research is needed.

MAIN TEXT

INTRODUCTION

Children had the lowest case notification rates in the early stages of the pandemic, though studies have since suggested this may have been related to increased frequencies of asymptomatic and mild illnesses in kids and lower testing rates rather than a decline in susceptibility (1). Children also seem to present, in principle, either no symptoms or have a milder clinical picture, leading to lower rates of hospitalisation or death compared to adults (3). Though the intensity or severity of the clinical manifestations of COVID-19 differs from those in adults in the short term, current data show that prolonged symptom duration also exists in children (4). However, in a small proportion of paediatric patients, severe complications could occur, as well as hospitalisations or even death (5).

Due to the novelty of SARS-CoV-2 and the rapid evolution of its variants, there is a paucity of data on the factors associated with severe COVID-19, especially in children, since many do not present with acute symptoms. This makes it imperative to identify the patient factors associated with severe COVID-19, which would indicate patient management pathways within the healthcare system and can be used to guide national decision-making bodies on COVID-19 mitigation strategies and may contribute to the evidence base for future respiratory pandemics. This systematic review and meta-analysis aims to identify the risk factors for adverse outcomes of COVID-19 within the paediatric population, using the recruitment setting (community vs. hospital) as a proxy of initial disease severity.

METHODS

The systematic review adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) (6) and MOOSE (Meta-analyses Of Observational Studies in Epidemiology) guidelines (7). The protocol of this systematic review was pre-reviewed by the European Centre for Disease Prevention and Control (ECDC). The protocol was not pre-registered in any database for systematic reviews.

Outcomes and Inclusion/exclusion criteria

Randomised controlled trials, non-randomised controlled trials, prospective and retrospective cohort studies, case-control studies, and analytical cross-sectional studies with no geographical limitation were considered eligible provided (i) they evaluated patients between the ages of 0-18 years old with clinically diagnosed or laboratory-confirmed COVID-19 in one of the following settings: community, hospital, intensive care unit (ICU); (ii) they assessed the associations between underlying conditions (as risk factors) and primary adverse outcomes of COVID-19. All underlying clinical conditions (risk factors) reported in the original studies were considered acceptable for data extraction.

Screening and data extraction

Relevant peer-reviewed studies published in English were identified within Medline (OVID) and EMBASE (OVID) from the start of the pandemic until 14 February 2022. Subject headings relating to COVID-19 and epidemiological study design terms were used to develop a comprehensive search strategy presented in **Appendix 1**. Reference lists of all included studies and identified reviews were also screened to identify additional relevant studies. Systematic and non-systematic literature reviews were excluded, but their references were screened. Full texts of potentially eligible studies were evaluated independently by two reviewers. Disagreements or uncertainties in the screening stages were resolved through discussion and consensus.

An ad hoc designed structured form was used for the adjusted data from each eligible study, including details on the study design, baseline characteristics of the participants, risk factors and outcome data. For accuracy, two reviewers extracted each study's data, and disagreements were discussed and resolved by a third reviewer. Adequate information was extracted to allow us to identify overlapping populations across studies; we prioritised including data from the study with the largest population and a more rigorously described methodology.

The methodological quality of each included study was evaluated independently by two reviewers using the Joanna Briggs Institute (JBI) standardised critical appraisal tool for the appropriate design (8). Disagreements were resolved with discussion and, when necessary, adjudication by a third reviewer. The results of the quality appraisal are presented in **Appendix 2**.

Assessing the certainty of the evidence

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used for evaluating the certainty in the body of evidence for each meta-analysis

(8). In line with GRADE recommendations for the assessment of the evidence of prognostic factors, we initially ascribed high certainty to all our findings. Studies were subsequently rated down according to several factors, including study limitations of the included studies, inconsistencies, indirectness or imprecision of the results, or evidence of publication bias. The level of certainty was rated up in cases of large observed effects.

Statistical Analysis

In anticipation of significant clinical and methodological heterogeneity in the meta-analyses, we fitted logistic regression models with random effects. All variables were dichotomous and analysed as Odds Ratios (OR) with corresponding 95% confidence intervals (95% C.I.). Heterogeneity was quantified using the I2 statistics. We considered values above 75% to represent considerable heterogeneity. To facilitate the interpretability of the results and in line with recommendations by GRADE (14), we also present the absolute Risk Differences (RD) per 1,000 COVID-19 patients with corresponding 95% C.I. The median prevalence of the evaluated risk factors and the median incidence rate of each adverse outcome in each recruitment setting were used for calculating the absolute RDs.

RESULTS

In the review, we included 47 studies involving 94,210 paediatric cases of COVID-19 (**PRISMA flowchart: Figure 1**). Recruitment dates ranged from 1 January 2020 to 24 September 2021 but were primarily based in 2020. There were 26 cohort studies (5, 9-33), 10 cross-sectional studies (34-43), seven chart reviews (44-50), three case-control studies (51-53) and one case series (54). Details on the characteristics of the included cohort studies are presented in **Table 1**.

As per our inclusion criteria, the studies had no geographical limitations. Twenty studies were conducted in the United States (US) (5, 11, 15, 17-23, 27, 31, 35, 36, 39, 47, 48, 50, 53, 54), two in Brazil (34, 49), and one in Canada (10). In addition, five studies took place in Europe, of which one in France (9), one in Switzerland (30), one in Spain (33), one in Poland (32) and one across 25 European countries (16). There were also five studies from Turkey (13, 14, 38, 40, 52), three studies from India (41, 45, 46), two from Pakistan (43, 44), two from Saudi Arabia (28, 29) and one from China (51). Finally, six studies combined data from across countries (12, 24-26, 37, 42). The diagnosis of COVID-19 was primarily performed with a PCR test, except for three studies where the diagnosis was made with the ICD Classification (5), was microbiologically confirmed (10) or was unknown (37).

Hospital admission among children recruited from the community setting

As noted in **Figure 2**, among children recruited from within the community setting (as a proxy of disease severity), neonates had higher odds of being hospitalised due to SARS-CoV-2 infection compared to older children (OR: 14.7; 95% CI: 6.8-31.8, $I^2=0\%$, high certainty). Similarly, infants under the age of 3 months (including neonates) were also more likely to be hospitalised (OR=7.9; 95% CI: 2.8-22.2, $I^2=0\%$, low certainty). Concerning BMI, underweight children (OR= 3.9, 95% CI: 2.1-7.1, $I^2=0\%$, moderate certainty) or severely obese (OR= 4.8, 95% CI: 1.9-12.1, $I^2=0\%$, low certainty) had higher odds for hospital admission. The presence of metabolic disorders also increased the odds of hospital admissions of SARS-CoV-2 infected children (OR= 29.6, 95% CI: 3.0-288.1, $I^2=0\%$, high certainty).

Concerning comorbidities (**Figure 3**), having at least one underlying disease was found to increase the odds of hospitalisation by 3.2 times (95% CI: 2.3-4.6, I^2 =58.8%, low certainty). Our metaanalyses indicated that children with underlying cardiovascular diseases were approximately five times more likely to be hospitalised (OR = 5.0, 95% CI: 4.3-5.8, I^2 = 0%, moderate certainty), followed by those with respiratory disorders (OR =3.5, 95% CI: 2.5-4.9, I^2 =20.4%, moderate certainty). Children with neuromuscular disorders were 3.2 times more likely to be hospitalised due to COVID-19, while the hospital admissions of those with neurologic conditions exceeded by 236 per 1,000 infections (95% CI: 78-336, I^2 =0%, moderate certainty) the respective admissions of COVID-19 paediatric patients without any neurologic condition (OR= 3.1, 95% CI: 1.4-6.9, I^2 =0%, moderate certainty). Elevated odds were additionally calculated for hospital admission with regards to pre-existing malignancies (OR=14.8, 95% CI: 2.1-106.5, I^2 =62.5%, low certainty), kidney disease (OR=9.5, 95% CI: 1.0-88.3, I^2 =0%, very low certainty) and haemato- immunological diseases (OR=6.3, 95% CI: 2.2-18.1, I^2 =67.2%, low certainty).

Mechanical ventilation, multisystem inflammatory syndrome in children (MIS-C), ICU admission and death among hospitalised children

Among the demographic characteristics of hospitalised paediatric patients presented in **Figure 4**, male gender (OR=1.3, 95% CI: 1.9-1.5, $I^2=0\%$, moderate certainty) and black race (OR=1.3, 95% CI: 1.1-1.5, $I^2=0\%$, moderate certainty) were associated with increased odds for the need of mechanical ventilation. Also, ICU admission was 1.5 times higher in black children (95% CI: 1.1-1.9, $I^2=13\%$, moderate certainty). Regarding MIS-C development following SARS-CoV-2 infection,

higher odds were estimated among those of black race (OR=1.3, 95% CI: 1.0-1.7, $I^2=13\%$, moderate certainty), and children aged between 5-12 years (OR=1.8, 95% CI: 1.0-3.3, $I^2=0\%$, low certainty) or over 10 years (OR=2.5; 95% CI: 1.5-4.14, $I^2=0\%$, low certainty). Neonates had lower odds of developing MIS-C (OR=0.3; 95% CI: 0.1-0.9, $I^2=0\%$, low certainty) compared to children of older ages.

Concerning underlying comorbidities (Figure 5), paediatric hospitalised patients with pre-existing conditions had higher odds (OR=2.5; 95% CI: 1.6-3.7, I^2 =67%, low certainty) of being admitted to ICU, while no statistically significant association was found for the need for mechanical ventilation and MIS-C development. The highest OR was estimated for children with congenital/genetic disease (OR=7.4, 95% CI: 2.4-22.7, I^2 =56.5%, low certainty), while obesity was associated with an elevated likelihood both for ICU admission (OR=2, 95% CI: 1.2-3.4, I^2 =59.1%, low certainty) and mechanical ventilation (OR=1.2, 95% CI: 1.0-1.4, I^2 =13%, moderate certainty) in hospitalised paediatric patients. Moreover, children with cancer were 60% (OR=1.6, 95% CI: 1.2-2.4, I^2 =0%, moderate certainty) and 150% (OR=2.5, 95% CI: 1.2-5.5, I^2 =0%, moderate certainty) more likely to be mechanically ventilated and admitted to ICU, respectively. Cardiovascular diseases were also identified as factors associated with both mechanical ventilation (OR=1.6, 95% CI: 1.3-2, I^2 =0%, moderate certainty) and ICU admission (OR=3.1, 95% CI: 2.5-3.7, I^2 =0%, moderate certainty). Finally, the pre-existence of any respiratory disease was associated with 2.7 higher odds of ICU admission (95% CI: 2-3.7, I^2 =0%, moderate certainty).

In contrast with the abovementioned findings, which show an increased risk for adverse COVID-19 outcomes, comorbidities seemed to be associated with lower odds for MIS-C development after SARS-CoV-2 infection, within the context of this review and for the timepoint of follow-up that was performed in the original studies. Children with a metabolic disorder were estimated to have approximately 50% smaller odds of developing MIS-C (OR=0.5, 95% CI: 0.2-0.9, $|^2=0\%$, moderate certainty). Likewise, neuromuscular disorders (OR=0.3, 95% CI: 0.1-0.6-1.4, $|^2=0\%$, moderate certainty), haemato-immunological disorders OR=0.6, 95% CI: 0.4-0.95, $|^2=0\%$, moderate certainty), cancer (OR=0.3, 95% CI: 0.1-0.8, $|^2=0\%$, moderate certainty) and asthma (OR=0.7, 95% CI: 0.5-0.6, $|^2=0\%$, moderate certainty) were also related to a decreased likelihood of MIS-C occurrence after SARS-CoV-2 infection. Finally, paediatric patients with kidney diseases had lower odds of being mechanically ventilated (OR=0.6, 95% CI: 0.4-0.6, $|^2=0\%$, moderate certainty).

We did not identify any demographic factors or comorbidities statistically significantly associated with death among hospitalised paediatric patients with COVID-19.

DISCUSSION

Our work reflects an extensive body of research on the risk factors linked to COVID-19 progression in paediatric patients. It is noteworthy that, within our study, we were able to use recruiting settings as a proxy for disease severity to divide study populations. In addition, we examined the COVID-19 endpoints separately, including hospital admission, ICU admission, mechanical ventilation, MIS-C, and death, as opposed to prior studies that aggregated these outcomes under the heading of severe COVID-19 progression.

According to the results of this comprehensive analysis, children and adolescents had higher odds of hospitalisation and ICU admission if they had specific demographic characteristics and concomitant conditions. Corroborating studies also highlight that the odds of a severe COVID-19 outcome are substantially elevated for children with underlying risk factors compared with healthy children(55), underscoring that two or more comorbidities rather than single entities pose a risk for more severe courses of SARS-CoV-2 infection in children (55, 56).

Hospitalisation, ICU admission and mechanical ventilation

Our meta-analysis focusing on global data indicated that among children recruited within the community setting, those younger than three months and neonates were more likely to be hospitalised, a finding which potentially could be interpreted as a clinical practice of caution for these early-aged patients, more than an index of disease severity. The existence of co-morbidities, such as metabolic disorders, as well as cardiovascular, haemato-immunological, kidney, respiratory, neurological, neuromuscular disorders and cancer were found to significantly affect the likelihood of hospital admission. This is in line with previous research both internationally (57), as well as from Europe (58), which has shown that the adjusted odds of hospitalisation were higher among paediatric cases with at least one comorbidity compared to healthy individuals. An additional finding of this study emphasised the significance of obesity in the hospitalisation of COVID-19 paediatric patients, which has been previously identified as a risk factor for severe COVID-19 in both adults and children (59, 60). Possible explanations for this relationship include a

decline in lung function, modifications to the microbiota, an increase in pro-inflammatory chemicals, and adjustments to the immune system (61), or simply this is a result of the application of the cautionary principle for this paediatric population. Concerning demographic characteristics, previous research has estimated that the likelihood of hospitalisation is highest in the youngest age groups in European countries, subsequently reduces with age until nine years, and then rises with each passing year from 12 to 17 years (58). However, the heightened odds of hospitalisation seen for children younger than two months may reflect lower thresholds for admission of infants and neonates (62). Therefore, hospitalisation indexes may not be an appropriate proxy for illness severity in this age group, and hence additional research is necessary to clarify this finding. Finally, literature originating from the US suggests that male gender and black/non-white ethnicity may also be risk factors for hospitalisation in COVID-19 paediatric patients (57, 58). However, these factors did not have a statistically significant association with hospitalisation in our meta-analysis.

With reference to ICU admission which could be noted as a core outcome of COVID-19 severity, only black ethnicity was significantly linked to elevated odds for COVID-19 paediatric patients among the demographic factors in our analysis, a factor which may be a proxy for other factors associated with the likelihood of hospitalisation, such as earlier access to healthcare etc. Previous systematic reviews and meta-analyses have indicated the effect of age (<1 month) and the male gender as risk factors for admission to the ICU (63). Our study demonstrated that the presence of comorbid disorders such as obesity, cancer, congenital/genetic, haemato-immune, respiratory, and cardiovascular diseases significantly increased the likelihood that COVID-19 paediatric patients would be admitted to ICU, a finding however which also applies to other viral infections and not only to SARS-CoV-2. In alignment with our findings, the pooled estimates presented in the review of Shi et al. (2021) showed that congenital heart disease, chronic pulmonary disease and obesity increased the odds of admission to ICU (63). As for mechanical ventilation, similarly to ICU admission, the statistically significant risk factors that were detected in our meta-analysis included male gender and black ethnicity, as well as obesity, cancer, and cardiovascular diseases.

MIS-C

In our meta-analysis, the odds for MIS-C development in COVID-19 paediatric patients were found to be increased in children older than 5 years old and of Black ethnicity. On the contrary, children younger than 1 month and those with metabolic, haemato-immunological, and neuromuscular disorders, along with asthma and cancer were estimated to have lower odds of developing MIS-C.

Our findings are supported by other systematic reviews with previous cut-off dates. According to the literature that is currently accessible, children who develop MIS-C are frequently previously healthy and typically in their early to middle childhood years. In the review of Rafferty et al. (64) ages ranged from 7 months to 20 years, with median ages ranging from 7 to 10 years. Additionally, despite some hypotheses that being overweight may enhance the probability of developing MIS-C, most studies reported little to no association (65). In contrast to an injury brought on by an acute SARS-CoV-2 infection, the recently described paediatric MIS appears to be the outcome of a chronic immune response (66). Moreover, as there is a lag time between SARS-CoV-2 infection and the development of MIS-C, it is possible that the follow-up time within the included studies may have been insufficient to catch all cases of MIS-C, hence, more research is required to draw firm conclusions.

Numerous research studies have suggested that African American, African/Afro-Caribbean, and Hispanic children may be disproportionately impacted by MIS-C in terms of race and ethnicity – however, this disparity is likely a result of health disparities and access to healthcare or other societal factors. African/Afro-Caribbean children frequently made up the largest percentage of cases in European studies with race/ethnicity data, ranging from 38 percent to 62 percent of MIS-C patients (65). The overrepresentation of black and Hispanic racial/ethnic groups among MIS-C patients may partly be due to the greater SARS-CoV-2 infection rates among these groups within the earlier phases of the pandemic (68, 69). Still, others have postulated that genetic predisposition might play a role in susceptibility to MIS-C (70, 71), while racial and ethnic minority groups are also generally more likely to encounter hurdles to healthcare access, exacerbating the issue (72, 73).

Death

Currently, given the small number of fatal cases in paediatric COVID-19 patients, the risk factors for mortality are scarce. In our study, no risk factors were significantly associated with increased odds of death. However, previous systematic reviews and meta-analyses demonstrated that underlying conditions are associated with increased odds of mortality, although estimated from very low-quality evidence. Additionally, age was appraised as a risk factor, with an increased likelihood among ages between four and ten years old (63). With regard to the role of comorbidities, in a recent review by Wijaya et al. (74), an increased risk for mortality was associated with malignancies, particularly haematological malignancies.

Strengths and limitations

Only peer-reviewed studies are included in this systematic review and meta-analysis, and study populations were segmented using recruiting settings as a proxy for disease severity. In addition, unlike earlier studies that combined severity outcomes under the category of severe COVID-19 development, we looked at the COVID-19 endpoints separately, including hospital admission, ICU admission, mechanical ventilation, MIS-C, and death. However, the limitations of our study should also be acknowledged as our results may be affected by confounding as the original studies included in this meta-analysis did not control for confounding factors and presented unadjusted odds. Furthermore, the included studies reflect mainly the pre-vaccination era, while only a few included data up to mid-2021. Furthermore, the research identified within this review does not provide information about different SARS-CoV-2 variants. Additionally, we included studies with no geographical limitation, which made it difficult to compare the results. However, since the results have similarities with European data (58), European physicians and policymakers may also benefit from them. Furthermore, there was evidence of heterogeneity as the definition of specific prognostic factors, such as congenital disorders, obesity, and respiratory disorders, were ambiguous in some of the included studies and variability in the definitions may have also contributed to the observed variability. Given that a direct comparison among different risk factors was not performed and similar effect sizes were found, no conclusions can be drawn on the comparative ranking or cumulative/synergistic effect of specific prognostic factors leading to COVID-related adverse outcomes. Nevertheless, conclusions on the individual impact of specific comorbidities can be drawn.

CONCLUSION

The findings of this systematic literature review and meta-analysis suggest that there were a number of factors associated with an increased likelihood of hospital, ICU admission, mechanical ventilation and MISC-2 in paediatric populations. It is unclear to which extent the increased hospital admission noted for younger children and for children with specific comorbidities (obesity, cancer, respiratory and cardiovascular disorders) were associated with disease severity or the application of precautionary clinical care for these higher-risk groups. It is notable however that these factors were also associated with ICU admission while certain comorbidities (obesity, cancer, and cardiovascular disease) were also associated with mechanical ventilation, an invasive procedure not easily classifiable as a preventative care measure, indicating that these factors also

play a role in disease severity as similarly noted among adults (75). This evidence may assist policymakers and public health authorities in emergency preparedness planning in the post-pandemic COVID-19 era.

Funding: European Centre for Disease Prevention and Control (ECDC) under specific contract No.

19 ECD.12254 within Framework contract ECDC/2019/001 Lot 1B.

Declaration of interests

We declare no competing interests.

Data sharing statement

Data sharing is not applicable to this article as no new data were created or analysed in this study.

REFERENCES

1. Lordan R, Prior S, Hennessy E, Naik A, Ghosh S, Paschos GK, et al. Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. Front Public Health. 2021;9:751451.

2. Hillis SD, Unwin HJT, Chen Y, Cluver L, Sherr L, Goldman PS, et al. Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study. Lancet. 2021;398(10298):391-402.

3. Shakeel S, Ahmad Hassali MA. Post-COVID-19 Outbreak of Severe Kawasaki-like Multisystem Inflammatory Syndrome in Children. Malays J Med Sci. 2021;28(1):109-16.

4. Asadi-Pooya AA, Nemati M, Nemati H. 'Long COVID': Symptom persistence in children hospitalised for COVID-19. Journal of Paediatrics and Child Health. 2022;58(10):1836-40.

5. Antoon JW, Grijalva CG, Thurm C, Richardson T, Spaulding AB, II RJT, et al. Factors Associated With COVID-19 Disease Severity in US Children and Adolescents. Journal of Hospital Medicine. 2021;16(10):603-10.

6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

7. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008-12.

8. Goldet G, Howick J. Understanding GRADE: an introduction. J Evid Based Med. 2013;6(1):50-4.

9. Ouldali N, Yang DD, Madhi F, Levy M, Gaschignard J, Craiu I, et al. Factors Associated With Severe SARS-CoV-2 Infection. Pediatrics. 2021;147(3).

10. Drouin O, Hepburn CM, Farrar DS, Baerg K, Chan K, Cyr C, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. Canadian Medical Association Journal. 2021;193(38):E1483.

11. Martin B, DeWitt PE, Russell S, Anand A, Bradwell KR, Bremer C, et al. Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative. JAMA Network Open. 2022;5(2):e2143151-e.

12. Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study. The Pediatric Infectious Disease Journal. 2021;40(1):e1-e6.

13. Okur DS. Clinical impact of COVID-19 on Turkish children with neurological and neuromuscular diseases: One center experience. Medicine. 2021;100(51):e28401.

14. Korkmaz MF, Türe E, Dorum BA, Kılıç ZB. The Epidemiological and Clinical Characteristics of 81 Children with COVID-19 in a Pandemic Hospital in Turkey: an Observational Cohort Study. J Korean Med Sci. 2020;35(25).

15. Kainth MK, Goenka PK, Williamson KA, Fishbein JS, Subramony A, Barone S, et al. Early Experience of COVID-19 in a US Children's Hospital. Pediatrics. 2020;146(4).

16. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci Fl, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-61.

17. Khan M, Dang L, Singh H, Dalrymple A, Miller A, Tanios A. Spectrum of SARS-CoV-2-Related Clinical Syndromes in Children: A Year in the Life. Clinical Pediatrics. 2022;61(2):188-93.

18. Graff K, Smith C, Silveira L, Jung S, Curran-Hays S, Jarjour J, et al. Risk Factors for Severe COVID-19 in Children. The Pediatric Infectious Disease Journal. 2021;40(4):e137-e45.

19. Kim TY, Kim EC, Agudelo AZ, Friedman L. COVID-19 hospitalization rate in children across a private hospital network in the United States: COVID-19 hospitalization rate in children. Archives de Pédiatrie. 2021;28(7):530-2.

20. Howard LM, Garguilo K, Gillon J, LeBlanc K, Seegmiller AC, Schmitz JE, et al. The first 1000 symptomatic pediatric SARS-CoV-2 infections in an integrated health care system: a prospective cohort study. BMC Pediatrics. 2021;21(1):403.

21. Verma S, Lumba R, Dapul HM, Gold-von Simson G, Phoon CK, Lighter JL, et al. Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan Area. Hospital Pediatrics. 2021;11(1):71-8.

22. Bhalala US, Gist KM, Tripathi S, Boman K, Kumar VK, Retford L, et al. Characterization and Outcomes of Hospitalized Children With Coronavirus Disease 2019: A Report From a Multicenter, Viral Infection and Respiratory Illness Universal Study (Coronavirus Disease 2019) Registry. Critical Care Medicine. 2022;50(1):e40-e51.

23. Bhumbra S, Malin S, Kirkpatrick L, Khaitan A, John CC, Rowan CM, et al. Clinical Features of Critical Coronavirus Disease 2019 in Children^{*}. Pediatric Critical Care Medicine. 2020;21(10):e948-e53.

24. Tripathi S, Gist KM, Bjornstad EC, Kashyap R, Boman K, Chiotos K, et al. Coronavirus Disease 2019–Associated PICU Admissions: A Report From the Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study Registry*. Pediatric Critical Care Medicine. 2021;22(7):603-15.

25. Tripathi S, Christison AL, Levy E, McGravery J, Tekin A, Bolliger D, et al. The Impact of Obesity on Disease Severity and Outcomes Among Hospitalized Children With COVID-19. Hosp Pediatr. 2021;11(11):e297-e316.

26. Funk AL, Florin TA, Kuppermann N, Tancredi DJ, Xie J, Kim K, et al. Outcomes of SARS-CoV-2–Positive Youths Tested in Emergency Departments: The Global PERN–COVID-19 Study. JAMA Network Open. 2022;5(1):e2142322-e.

27. Fisler G, Izard SM, Shah S, Lewis D, Kainth MK, Hagmann SHF, et al. Characteristics and risk factors associated with critical illness in pediatric COVID-19. Annals of Intensive Care. 2020;10(1):171.

28. Alfraij A, Bin Alamir AA, Al-Otaibi AM, Alsharrah D, Aldaithan A, Kamel AM, et al. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) in critically ill pediatric patients admitted to the intensive care unit: A multicenter retrospective cohort study. Journal of Infection and Public Health. 2021;14(2):193-200.

29. Alharbi M, Kazzaz YM, Hameed T, Alqanatish J, Alkhalaf H, Alsadoon A, et al. SARS-CoV-2 infection in children, clinical characteristics, diagnostic findings and therapeutic interventions at a tertiary care centre in Riyadh, Saudi Arabia. Journal of Infection and Public Health. 2021;14(4):446-53.

30. Uka A, Buettcher M, Bernhard Stirnemann S, Fougère Y, Moussaoui D, Kottanattu L, et al. Correction to: Factors associated with hospital and intensive care admission in paediatric SARS CoV 2 infection: a prospective nationwide observational cohort study. European Journal of Pediatrics. 2022;181(3):1257-.

31. Farzan S, Rai S, Cerise J, Bernstein S, Coscia G, Hirsch JS, et al. Asthma and COVID-19: An early inpatient and outpatient experience at a US children's hospital. Pediatric Pulmonology. 2021;56(8):2522-9.

32. Mania A, Faltin K, Mazur-Melewska K, Małecki P, Jończyk-Potoczna K, Lubarski K, et al. Clinical Picture and Risk Factors of Severe Respiratory Symptoms in COVID-19 in Children. Viruses. 2021;13(12):2366.

33. de Ceano-Vivas M, Martín-Espín I, del Rosal T, Bueno-Barriocanal M, Plata-Gallardo M, Ruiz-Domínguez JA, et al. SARS-CoV-2 infection in ambulatory and hospitalised Spanish children. Archives of Disease in Childhood. 2020;105(8):808.

34. Marques HHS, Pereira MFB, Santos ACD, Fink TT, Paula CSY, Litvinov N, et al. Differences in children and adolescents with SARS-CoV-2 infection: a cohort study in a Brazilian tertiary referral hospital. Clinics (Sao Paulo). 2021;76:e3488.

35. Diorio C, Henrickson SE, Vella LA, McNerney KO, Chase J, Burudpakdee C, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2. The Journal of Clinical Investigation. 2020;130(11):5967-75.

36. Snowden J, Patwardhan A. Association Between Age and Ethnicity with Pediatric Clinical Outcomes in COVID-2019. Global Pediatric Health. 2021;8:2333794X211033451.

37. Moeller A, Thanikkel L, Duijts L, Gaillard EA, Garcia-Marcos L, Kantar A, et al. COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres. ERJ Open Research. 2020;6(4):00409-2020.

38. Beken B, Ozturk GK, Aygun FD, Aydogmus C, Akar HH. Asthma and allergic diseases are not risk factors for hospitalisation in children with coronavirus disease 2019. Ann Allergy Asthma Immunol. 2021;126(5):569-75.

39. Nino G, Molto J, Aguilar H, Zember J, Sanchez-Jacob R, Diez CT, et al. Chest X-ray lung imaging features in pediatric COVID-19 and comparison with viral lower respiratory infections in young children. Pediatr Pulmonol. 2021;56(12):3891-8.

40. Göktuğ A, Güngör A, Öz FN, Akelma Z, Güneylioğlu MM, Yaradılmış RM, et al. Evaluation of Epidemiological, Demographic, Clinical Characteristics and Laboratory Findings of COVID-19 in the Pediatric Emergency Department. Journal of Tropical Pediatrics. 2021;67(4).

41. Chopra S, Saha A, Kumar V, Thakur A, Pemde H, Kapoor D, et al. Acute Kidney Injury in Hospitalized Children with COVID19. Journal of Tropical Pediatrics. 2021;67(2).

42. Martínez-García JJ, Luna-Méndez JE, Alarid-Coronel D, Lares-Payan A, Picasso-López DE, León-Sicairos NM, et al. Clinical and epidemiological characteristics of COVID-19 in children: experience in two hospitals. Bol Med Hosp Infant Mex. 2021;78(6):506-14.

43. Aimen C, Bari A, Rashid J, Alvi Y, Naz F, Rana N, et al. Comorbidity and covid-19 in childrena single center experience. Pakistan Paediatric Journal. 2020:306-13.

44. Shahid S, Raza M, Junejo S, Maqsood S. Clinical features and outcome of COVID-19 positive children from a tertiary healthcare hospital in Karachi. J Med Virol. 2021;93(10):5988-97.

45. Kapoor D, Kumar V, Pemde H, Singh P. Impact of Comorbidities on Outcome in Children With COVID-19 at a Tertiary Care Pediatric Hospital. Indian Pediatr. 2021;58(6):572-5.

46. Rao S, Gavali V, Prabhu SS, Mathur R, Dabre LR, Prabhu SB, et al. Outcome of Children Admitted With SARS-CoV-2 Infection: Experiences From a Pediatric Public Hospital. Indian Pediatrics. 2021;58(4):358-62.

47. Grewal MK, Gregory MJ, Jain A, Mohammad D, Cashen K, Ang JY, et al. Acute Kidney Injury in Pediatric Acute SARS-CoV-2 Infection and Multisystem Inflammatory Syndrome in Children (MIS-C): Is There a Difference? Front Pediatr. 2021;9:692256.

48. Chao JY, Derespina KR, Herold BC, Goldman DL, Aldrich M, Weingarten J, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically III Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. J Pediatr. 2020;223:14-9.e2.

49. Oliveira E, Colosimo E, Simões e Silva A, Mak R, Martelli D, Silva L, et al. Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database. The Lancet Child & Adolescent Health. 2021;5.

50. Bhavsar SM, Clouser KN, Gadhavi J, Anene O, Kaur R, Lewis R, et al. COVID-19 in Pediatrics: Characteristics of Hospitalized Children in New Jersey. Hospital Pediatrics. 2021;11(1):79-87.

51. Wang Y, Zhu F, Wang C, Wu J, Liu J, Chen X, et al. Children Hospitalized With Severe COVID-19 in Wuhan. The Pediatric Infectious Disease Journal. 2020;39(7).

52. Metbulut AP, Mustafaoğlu Ö, Şen G, Kanık Yüksek S, Külhaş Çelik İ, Akça H, et al. Evaluation of the Clinical and Laboratory Findings of Asthmatic Children with SARS-CoV-2 Infection. International Archives of Allergy and Immunology. 2021;182(10):989-96.

53. Gaietto K, Freeman MC, DiCicco LA, Rauenswinter S, Squire JR, Aldewereld Z, et al. Asthma as a risk factor for hospitalization in children with COVID-19: A nested case-control study. Pediatric Allergy and Immunology. 2022;33(1):e13696.

54. Webb NE, Osburn TS. Characteristics of Hospitalized Children Positive for SARS-CoV-2: Experience of a Large Center. Hospital Pediatrics. 2021;11(8):e133-e41.

55. Ankermann T, Brinkmann F. Comorbidities in Children with COVID-19 and MIS-C/PIMS-TS and Risk Factors for Hospitalization, Severe Disease, Intensive Care and Death. Klin Padiatr. 2022;234(05):257-66.

56. Choi JH, Choi S-H, Yun KW. Risk Factors for Severe COVID-19 in Children: A Systematic Review and Meta-Analysis. J Korean Med Sci. 2022;37(5).

57. Tsankov BK, Allaire JM, Irvine MA, Lopez AA, Sauvé LJ, Vallance BA, et al. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis. Int J Infect Dis. 2021;103:246-56.

58. Bundle N, Dave N, Pharris A, Spiteri G, Deogan C, Suk JE, et al. COVID-19 trends and severity among symptomatic children aged 0–17 years in 10 European Union countries, 3 August 2020 to 3 October 2021. Eurosurveillance. 2021;26(50):2101098.

59. La Fauci G, Montalti M, Di Valerio Z, Gori D, Salomoni MG, Salussolia A, et al. Obesity and COVID-19 in Children and Adolescents: Reciprocal Detrimental Influence-Systematic Literature Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(13).

60. Oliveira da Silva Kist ML, Hanzen Andrades GR, Drumond Costa CA, Crestani F, Ramos Garcia PC. Weight excess association with severity in children and adolescents with COVID-19: A systematic review. Clinical Nutrition ESPEN. 2022;49:114-20.

61. Fedele D, De Francesco A, Riso S, Collo A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. Nutrition. 2021;81:111016.

62. Wallace B, Chang D, Woodworth K, DeSisto CL, Simeone R, Ko JY, et al. Illness severity indicators in newborns by COVID-19 status in the United States, March–December 2020. Journal of Perinatology. 2022;42(4):446-53.

63. Shi Q, Wang Z, Liu J, Wang X, Zhou Q, Li Q, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis. eClinicalMedicine. 2021;41.

64. Rafferty MS, Burrows H, Joseph JP, Leveille J, Nihtianova S, Amirian ES. Multisystem inflammatory syndrome in children (MIS-C) and the coronavirus pandemic: Current knowledge and implications for public health. J Infect Public Health. 2021;14(4):484-94.

65. Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis. Pediatric Pulmonology. 2021;56(5):837-48.

66. Tsabouri S, Makis A, Kosmeri C, Siomou E. Risk Factors for Severity in Children with Coronavirus Disease 2019: A Comprehensive Literature Review. Pediatric Clinics. 2021;68(1):321-38.

67. Sarfraz M, Sarfraz A, Sarfraz Z, Nadeem Z, Khalid J, Butt SZ, et al. Contributing factors to pediatric COVID-19 and MIS-C during the initial waves: A systematic review of 92 case reports. Annals of Medicine and Surgery. 2022;81:104227.

68. Mannheim J, Konda S, Logan LK. Racial, ethnic and socioeconomic disparities in SARS-CoV-2 infection amongst children. Paediatr Perinat Epidemiol. 2022;36(3):337-46.

69. Goyal MK, Simpson JN, Boyle MD, Badolato GM, Delaney M, McCarter R, et al. Racial and/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children. Pediatrics. 2020;146(4).

70. Lee PY, Day-Lewis M, Henderson LA, Friedman KG, Lo J, Roberts JE, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130(11):5942-50.

71. Rogo T, Mathur K, Purswani M. Systemic Inflammation With Cardiac Involvement in Pediatric Patients With Evidence of COVID-19 in a Community Hospital in the Bronx, New York. J Pediatric Infect Dis Soc. 2020;9(4):502-3.

72. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020;4(9):669-77.

73. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074-80.

74. Wijaya JT, Varshney K, Browning SD, Fatima SZ, Shahrin L. Risk Factors for COVID-19 Mortality in Pediatric Populations: A Scoping Review. Research Square; 2022.

75. Vardavas Cl, Mathioudakis AG, Nikitara K, Stamatelopoulos K, Georgiopoulos G, Phalkey R, Leonardi-Bee J, Fernandez E, Carnicer-Pont D, Vestbo J, Semenza JC, Deogan C, Suk JE, Kramarz P, Lamb F, Penttinen P. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. Eur Respir Rev. 2022 Nov 2;31(166):220098. doi: 10.1183/16000617.0098-2022. PMID: 36323422; PMCID: PMC9724816.

Table 1. Methodological characteristics of included studies related to adverse outcomes of COVID-19 in children

FIRST AUTHOR,	COUNTRY, CITY	SETTING AT ENROLLMENT	STUDY DESIGN	RECRUITMENT DATES	COVID DIAGNOSIS
YEAR OF PUBLICATION					
Shahid et al., 2021 (44)	Pakistan, Karachi	Hospital, community	Retrospective chart review	April to July 2020	RT-PCR
Wang et al., 2020 (51)	China, Wuhan	Hospital	Retrospective case-control	January 25 to March 8, 2020	RT-PCR
Drouin et al., 2021 (10)	Canada	Hospital	National prospective study	April 8 to December 31, 2020	Microbiologically confirmed
Marques et al., 2021 (34)	Brazil, São Paulo	Hospital, community	Cross-sectional study	April 11, 2020 to April 22, 2021	RT-PCR, serological tests
Diorio et al., 2020 (35)	US, Philadelphia	Hospital	Cross-sectional study	April 3 to May 15, 2020	RT-PCR, serological tests
Snowden et al., 2021 (36)	US, Arkansas	Hospital, community	Cross-sectional study	February 1 to August 30, 2020	RT-PCR
Martin et al., 2022 (11)	US	Hospital, community	Prospective cohort study	up to September 24, 2021	PCR, antigen or antibody test
Moeller et al., 2020 (37)	Within and outside of Europe	Hospital, community	ERS Survey/ Cross-sectional study	April and May 2020	Unknown
Antunez-Montes 2021 (12)	Mexico, Colombia, Peru, Costa Rica, Brazil	Hospital	Multicenter cohort study	July 1 to August 11, 2020	RT-PCR
Okur et al., 2021 (13)	Turkey, Denizli	Hospital	Retrospective study	March 18, 2020, to January 18, 2021	RT-PCR
Ouldali et al., 2021 (9)	France	Hospital, Community	National prospective cohort	February 15 to June 1, 2020	RT-PCR, CT
Korkmaz et al., 2020 (14)	Turkey, Bursa	Hospital, Community	Retrospective observational cohort study	March 5 to May 5, 2020	RT-PCR
Beken et al., 2021 (38)	Turkey, Istanbul	Community (ER)	Cross-sectional study	March 15 to May 31, 2020	RT-PCR, CT
Nino et al., 2021 (39)	US, Washington	Community	Cross-sectional study	March to June 2020	RT-PCR
Goktug et al., 2021 (40)	Turkey, Ankara	Hopsital	Cross-sectional study	March to December 2020	RT-PCR
Kainth et al., 2020 (15)	US, New York	Hospital	Single-centre retrospective cohort study	January 23 to April 23, 2020	RT-PCR
Kapoor et al., 2021 (45)	India	Hospital	Case record review	March to December 2020	RT-PCR
Antoon et al., 2021 (5)	US	Hospital	Multicenter retrospective cohort study	April to September 2020	ICD-10 codes U.071 and U.072

Chopra et al., 2021 (41)	India, New Delhi	Hospital	Cross-sectional analysis	March to November 2020	RT-PCR
Gotzinger et al., 2020 (16)	25 European countries	Hospital	Multicentre cohort study	April 1 to April 24, 2020	RT-PCR
Rao et al., 2021 (46)	India, Mumbai	Hospital	Retrospective medical record review	March 19 to August 7, 2020	RT-PCR
Khan et al., 2021 (17)	US, Saint Louis	Hospital	Retrospective cohort study	March 1, 2020, to February 28, 2021	RT-PCR
Graff et al., 2021 (18)	US, Colorado	Hospital, Community	Retrospective cohort study	March to July 2020	RT-PCR
Kim et al., 2021 (19)	US	Hospital, Community	Retrospective analysis	January 1 to July 24, 2020	Any positive test result
Howard et al., 2021 (20)	US	Hospital, Community	Prospective cohort study	March 13 to September 28, 2020	RT-PCR
Verma et al., 2021 (21)	US, New York	Hospital	Multicenter retrospective cohort study	March 1 to May 10, 2020	RT-PCR
Martinez-Garcia et al., 2021 (42)	Mexico, Culiacán, Sinaloa	Hospital	Retrospective cross-sectional study	April 1 to June 30, 2020	RT-PCR
Metbulut et al., 2021 (52)	Turkey, Ankara	Hospital, Community	Retrospective, case-control study	March 11 to November 10, 2020	RT-PCR
Gaietto et al., 2022 (53)	US, Pittsburg	Community	Nested case-control stud	March 11 to December 21, 2020	RT-PCR
Grewal et al., 2021 (47)	US, Michigan	Hospital	Retrospective chart review	March to August 2020	RT-PCR, antibody test
Chao et al., 2020 (48)	US, Montefiore	Hospital	Retrospective chart review	March 15 to April 13, 2020	RT-PCR
Bhumbra et al., 2020 (23)	US, Indianapolis	Hospital	Observational cohort study	up to May 4, 2020	RT-PCR
Funk et al., 2022 (26)	Argentina, Australia, Canada, Costa Rica, Italy, New Zealand, Paraguay, Singapore, Spain, and the US	Community	Prospective cohort study	March 2020 to June 2021	RT-PCR
Oliveira et al., 2021 (49)	Brazil	Hospital	Retrospective chart review	Feb 16, 2020 to January 9, 2020	RT-PCR
Bhavsar et al., 2021 (50)	US, New Jersey	Hospital	Retrospective chart review	March 1 to May 31, 2020	RT-PCR, serum IgG
Fisler et al., 2020 (27)	US, New York	Hospital	Retrospective cohort study	February 1 to April 24, 2020	RT-PCR
Alfraij et al., 2021 (28)	Kuwait and Saudi Arabia	Hospital	Multicenter, retrospective, cohort study	March 1 to August 1, 2020	RT-PCR

Alharbi et al., 2021 (29)	Saudi Arabia, Riyadh	Hospital, Community	Retrospective cohort study	April 7 to July 17, 2020	RT-PCR
Uka et al., 2022 (30)	Switzerland	Hospital, Community	Prospective nationwide observational cohort study	March 1 to October 31, 2020	RT-PCR or serology
Farzan et al., 2021 (31)	USA, New York	Hospital	Retrospective cohort study	March to July 2020	RT-PCR
Mania et al., 2021 (32)	Poland, Poznan	Hospital	Retrospective cohort study	March 2020 to April 2021	RT-PCR, antigen test
De Ceano-Vivas 2020 (33)	Spain, Madrid	Community	Retrospective cohort study	March 11 to April 9, 2020	RT-PCR
Bhalala et al., 2022 (22)	USA	Hospital	Retrospective cohort study	February 2020 to January 2021	RT-PCR
Aimen et al., 2020 (43)	Pakistan	Hospital	Descriptive cross-sectional study	March 15 to July 31, 2020	RT-PCR
Tripathi et al., 2021 (25)	USA but data from 28 countries	Hospital	Retrospective cohort study	March 2020 to January 2021	RT-PCR, antibody test
Tripathi et al., 2021b (24)	USA but data from 28 countries	Hospital	Retrospective cohort study	March 2020 to January 2021	RT-PCR, antibody test
Webb et al., 2021 (54)	USA, California	Hospital	Retrospective case series	May 1 to September 30, 2020	RT-PCR, antigen, IgG

Figure 1. Flowchart1

medRxiv preprint doi: https://doi.org/10.1101/2024.02.23.23298451; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



📦 covidence



Figure 2. Demographic characteristics and COVID-19 severity outcomes among children recruited from the community setting

Footnote: N refers to the number of studies, n the number of SARS-CoV2 patients in those studies, the weighting of the assessment by GRADE, and the I2 of each meta-analysis is provided



Figure 3. Underlying comorbidities and COVID-19 severity outcomes among children recruited from the community setting

Footnote: N refers to the number of studies, n the number of SARS-CoV2 patients in those studies, the weighting of the assessment by GRADE, and the I2 of each meta-analysis is

provided



Figure 4. Demographic characteristics and COVID-19 severity outcomes among hospitalised paediatric patients

Footnote: N refers to the number of studies, n the number of SARS-CoV2 patients in those studies, the weighting of the assessment by GRADE, and the I2 of each meta-analysis is provided

			Setting: Hospital				
Prognostic factor	Outcome		N(n)	Main analysis: OR [95% C.I.]	1^2	Absolute Risk Difference [95% C.I.]	GRADE
Comorbidities	MIS-C	Ŧ	4 (9502)	0.676 [0.443-1.032]	30.45	69 fewer per 1000, [-141 to 6]	Low
Comorbidities	Mechanical Ventilation	Ī	2 (243)	0.795 [0.412-1.534]	0	34 fewer per 1000, [-128 to 64]	Very low
Comorbidities	Death	Ī	2 (243)	1.119 [0.279-4.477]	74.25	7 more per 1000, [-76 to 88]	Very low
Comorbidities	ICU admission	Ŧ	10 (5751)	2.469 [1.634-3.729]	68.94	211 more per 1000, [116 to 302]	Low
Comorbidities	Severe pneumonia	ł	2 (193)	2.63 [1.389-4.979]	0	230 more per 1000, [80 to 368]	Very low
Underweight	ICU admission	Ŧ	2 (945)	0.925 [0.582-1.471]	0	18 fewer per 1000. [-120 to 94]	Low
Overweight	ICU admission	Ŧ	2 (919)	0.849 [0.572-1.26]	0	38 fewer per 1000, [-125 to 56]	Low
Obesity	MIS-C		2 (8969)	0.66 [0.065-6.655]	81.3	72 fewer per 1000. [-319 to 334]	Very low
Obesity	Mechanical Ventilation		2 (10283)	1.188 [1.001-1.41]	0	26 more per 1000. [0 to 53]	Moderate
Obesity	ICU admission	ł	4 (1818)	1.992 [1.166-3.403]	59.07	165 more per 1000, [37 to 289]	Low
Metabolic	MIS-C	ł	1 (8948)	0.47 [0.246-0.897]	0	110 fewer per 1000, [-168 to -19]	Moderate
Metabolic	Mechanical Ventilation	-8	1 (10245)	1.11 [0.949-1.298]	0	16 more per 1000. [-8 to 42]	Low
Metabolic	ICU admission		1 (71)	2.591 [0.216-31.097]	0	234 more per 1000, [-276 to 585]	Very low
Asthma	MIS-C	Ŧ	1 (8948)	0.66 [0.487-0.894]	0	68 fewer per 1000, [-109 to -19]	Moderate
Asthma	Mechanical Ventilation	ł	2 (10283)	0.826 [0.511-1.333]	7.5	27 fewer per 1000, [-85 to 46]	Low
Asthma	ICU admission	Ŧ	5 (5124)	1.096 [0.757-1.587]	32	22 more per 1000, [-64 to 113]	Low
Cancer	MIS-C	Ī	1 (8948)	0.32 [0.121-0.847]	0	149 fewer per 1000, [-208 to -29]	Moderate
Cancer	ICU admission		1 (67)	1.576 [0.15-16.58]	0	111 more per 1000, [-315 to 546]	Very low
Cancer	Mechanical Ventilation	Ŧ	2 (10310)	1.698 [1.184-2.436]	0	91 more per 1000, [27 to 165]	Moderate
Cardiovascular	MIS-C	Ŧ	1 (8948)	1.38 [0.951-2.002]	0	61 more per 1000, [-9 to 141]	Low
Cardiovascular	Mechanical Ventilation	2	2 (10310)	1.578 [1.284-1.939]	0	76 more per 1000, [40 to 116]	Moderate
Cardiovascular	ICU admission	ō	3 (4211)	3.073 [2.548-3.707]	0	274 more per 1000, [229 to 316]	Moderate
Congenital, Genetic	MIS-C	ł	1 (8948)	0.61 [0.29-1.282]	0	77 fewer per 1000, [-154 to 47]	Low
Congenital, Genetic	Mechanical Ventilation	<u>.</u>	1 (10245)	1.1 [0.898-1.347]	0	15 more per 1000, [-16 to 49]	Low
Congenital, Genetic	ICU admission	I	5 (1982)	7.383 [2.399-22.718]	56.48	440 more per 1000, [215 to 557]	Low
Developmental, Behavioral	ICU admission	Ī	1 (874)	1.653 [0.96-2.847]	0	123 more per 1000, [-10 to 256]	Low
Gastrointestinal	MIS-C	ł	1 (8948)	1.03 [0.431-2.464]	0	5 more per 1000. [-118 to 193]	Low
Gastrointestinal	Mechanical Ventilation	Ŧ	1 (10245)	1.09 [0.781-1.522]	0	13 more per 1000, [-34 to 71]	Low
Hemato-, Immuno-logical	MIS-C	Ŧ	2 (9357)	0.591 [0.366-0.955]	0	84 fewer per 1000, [-142 to -8]	Moderate
Hemato-, Immuno-logical	Mechanical Ventilation	Ŧ	2 (10310)	0.841 [0.637-1.108]	0	25 fewer per 1000, [-61 to 16]	Low
Hemato-, Immuno-logical	ICU admission	ļ	3 (4549)	1.937 [0.539-6.966]	91.5	162 more per 1000. [-137 to 445]	Very low
Hematological	Death	ļ	1 (62)	0.8 [0.151-4.242]	0	14 fewer per 1000, [-61 to 167]	Very low
Hematological	ICU admission		1 (77)	1.586 [0.095-26.417]	0	113 more per 1000, [-339 to 565]	Very low
Kidney	Mechanical Ventilation	Ŧ	1 (10245)	0.59 [0.433-0.805]	0	75 fewer per 1000, [-114 to -32]	Moderate
Kidney	Death		1 (19)	0.833 [0.062-11.234]	0	12 fewer per 1000, [-101 to 149]	Very low
Kidney	MIS-C	Ī	1 (8948)	1.46 [0.743-2.87]	0	69 more per 1000, [-52 to 195]	Low
Kidney	ICU admission	I 	2 (601)	2.895 [0.813-10.305]	0	253 more per 1000, [-49 to 520]	Low
Malgnancy	ICU admission	Ī	3 (741)	2.537 [1.173-5.49]	0	228 more per 1000. [38 to 399]	Moderate
Malgnancy	Death		1 (19)	7.5 [0.325-173.17]	0	209 more per 1000. [-52 to 484]	Very low
Neurologic disorders	Death		1 (62)	1.045 [0.106-10.302]	0	3 more per 1000, [-66 to 332]	Very low
Neurologic disorders	ICU admission		5 (1461) • (sole)	3.591 [0.983-13.118] 0.25 IO 44 0.5601	66.86	308 more per 1000. [-4 to 515]	Very low
Neuromuscular			1 (0340)	[60C:0-11:0] CZ:0	5	174 tewer per 1000, [-220 to -66]	MODErate
Neuromuscular	Mechanical Ventilation	Į	2 (10310)	1.43 [0.654-3.125]	25.17	58 more per 1000, [-57 to 214]	Low
Neuromuscular	ICU admission		2 (4325)	6.023 [0.385-94.304]	95.82	415 more per 1000. [-199 to 659]	Very low
Non-tubercular co-infections	Death	ļ	1 (62)	1.056 [0.245-4.546]	0	4 more per 1000, [-64 to 123]	Very low
Respiratory	MIS-C	ŀ	1 (8948)	0.75 [0.289-1,945]	0	47 fewer per 1000, [-153 to 138]	Low
Respiratory	ICU admission	Ŧ	4 (4804)	2.676 [1.927-3.718]	0	241 more per 1000, [162 to 314]	Moderate
Respiratory	Mechanical Ventilation		2 (10310)	3,403 [0.366-31.644]	69.95	248 more per 1000, [-109 to 695]	Very low
Transplant	Mechanical Ventilation	Ī	1 (10245)	1.21 [0.705-2.076]	0		Low
Tuberculosis	Death	I	1 (62)	1.062 [0.278-4.056]	0	4 more per 1000, [-65 to 101]	Very low
	0.01	0.1 0.5 1 2 10 100 Odds ratio, 95% CI					

Figure 5. Underlying comorbidities and COVID-19 severity outcomes among hospitalised paediatric patients

Footnote: N refers to the number of studies, n the number of SARS-CoV2 patients in those studies, the weighting of the assessment by GRADE, and the I2 of each meta-analysis is provided